MRIdian "RADAR" Trial
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Miami
About this trial
The main purpose of this study is to see if treating cancer with the magnetic resonance imaging guided adaptive radiotherapy (MRIdian) can control patient's tumor and eliminate the need for surgery used to treat nerves in the spine flattened by pressure (compressed).
Eligibility criteria
Qualifiers
Male and female participants ages ≥ 18.
Solid tumors causing MESCC for which surgery is an option as first-line treatment.
Tumor histologies eligible for treatment include breast, prostate, sarcoma, melanoma, gastrointestinal types, NSCLC and renal cancers. Other solid malignancy types are also allowed at discretion of investigator if not specifically excluded by criteria.
MRI of involved spine within 4 weeks prior to registration to determine extent of spine involvement.
Disqualifiers
Unknown primary histology
Patients with rapid neurologic decline.
Bony retropulsion causing neurologic abnormality
Non-ambulatory patients.
Trial design
Treatments tested in this trial
- ViewRay MRIdian Stereotactic Radiosurgery
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Miami
Lead sponsor
Viewray Inc.
Collaborator
Source ClinicalTrials.gov